CN1993325A - 作为组胺h3受体配体的哌啶衍生物 - Google Patents

作为组胺h3受体配体的哌啶衍生物 Download PDF

Info

Publication number
CN1993325A
CN1993325A CNA2005800262732A CN200580026273A CN1993325A CN 1993325 A CN1993325 A CN 1993325A CN A2005800262732 A CNA2005800262732 A CN A2005800262732A CN 200580026273 A CN200580026273 A CN 200580026273A CN 1993325 A CN1993325 A CN 1993325A
Authority
CN
China
Prior art keywords
base
group
benzo
dihydro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800262732A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·福尔默
西蒙·F·亨特
彼得·汉利
史蒂文·韦索洛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1993325A publication Critical patent/CN1993325A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2005800262732A 2004-08-02 2005-07-27 作为组胺h3受体配体的哌啶衍生物 Pending CN1993325A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0401971A SE0401971D0 (sv) 2004-08-02 2004-08-02 Piperidne derivatives
SE04019717 2004-08-02

Publications (1)

Publication Number Publication Date
CN1993325A true CN1993325A (zh) 2007-07-04

Family

ID=32906883

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800262732A Pending CN1993325A (zh) 2004-08-02 2005-07-27 作为组胺h3受体配体的哌啶衍生物

Country Status (14)

Country Link
US (1) US20080064706A1 (https=)
EP (1) EP1781613A1 (https=)
JP (1) JP2008508353A (https=)
KR (1) KR20070043998A (https=)
CN (1) CN1993325A (https=)
AU (1) AU2005267932A1 (https=)
BR (1) BRPI0514035A (https=)
CA (1) CA2576112A1 (https=)
IL (1) IL180548A0 (https=)
MX (1) MX2007001226A (https=)
RU (1) RU2007105970A (https=)
SE (1) SE0401971D0 (https=)
WO (1) WO2006014136A1 (https=)
ZA (1) ZA200700683B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113103A1 (en) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
CN106170485A (zh) * 2014-03-07 2016-11-30 赫尔辛医疗股份公司 对位取代的不对称脲及其医疗用途
CN106536518A (zh) * 2014-05-19 2017-03-22 梅里亚股份有限公司 驱蠕虫化合物
CN113549006A (zh) * 2020-04-26 2021-10-26 江苏恩华药业股份有限公司 一种酰胺衍生物及其应用

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
AR055831A1 (es) 2004-12-30 2007-09-12 Janssen Pharmaceutica Nv Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
US7851474B2 (en) 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
EP2170836A1 (en) * 2007-06-22 2010-04-07 F. Hoffmann-Roche AG Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors
BRPI0820432B8 (pt) 2007-11-13 2021-05-25 Taisho Pharmaceutical Co Ltd derivados de fenilpirazol apresentando atividade de antagonista de receptor de histamina h3 e um agente profilático ou terapeutico compreendendo tais derivados
US8598356B2 (en) 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
TW201039822A (en) 2009-02-06 2010-11-16 Taisho Pharmaceutical Co Ltd Dihydroquinolinone derivatives
CN106883246B (zh) 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
TW201321353A (zh) 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
EP2789608A4 (en) 2011-12-08 2015-07-01 Taisho Pharmaceutical Co Ltd PHENYLPYRROLDERIVAT
TW201343636A (zh) 2011-12-27 2013-11-01 大正製藥股份有限公司 苯基三唑衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
EP3383853B1 (en) 2015-12-01 2020-11-04 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease
CN108884026B (zh) 2016-03-22 2021-05-25 赫尔森保健股份公司 苯磺酰基不对称尿素及其医学用途
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
PL3571193T3 (pl) 2017-01-23 2022-04-25 Cadent Therapeutics, Inc. Modulatory kanału potasowego
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
EP3870291A1 (en) 2018-10-22 2021-09-01 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
CN111349609A (zh) * 2018-12-21 2020-06-30 泰州医药城国科化物生物医药科技有限公司 一种无标记组胺受体h3的细胞筛选模型
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
WO2020232056A1 (en) * 2019-05-13 2020-11-19 The Regents Of The University Of California Compositions and methods for the treatment of neurological diseases and disorders
WO2021016414A1 (en) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
ES2819309B2 (es) * 2019-10-14 2021-11-17 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE60234616D1 (de) * 2001-09-14 2010-01-14 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US7064135B2 (en) * 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
US20060052597A1 (en) * 2002-10-22 2006-03-09 Best Desmond J Aryloxyalkylamine derivatives as h3 receptor ligands
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
AU2004274309B2 (en) * 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113103A1 (en) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
CN103874492A (zh) * 2011-02-25 2014-06-18 赫尔辛卫生保健公司 不对称脲及其医学应用
AP3768A (en) * 2011-02-25 2016-08-31 Helsinn Healthcare Sa Asymmetric ureas and medical uses thereof
CN103874492B (zh) * 2011-02-25 2016-12-07 赫尔辛卫生保健公司 不对称脲及其医学应用
CN106995403A (zh) * 2011-02-25 2017-08-01 赫尔辛卫生保健公司 不对称脲及其医学应用
CN106995403B (zh) * 2011-02-25 2020-04-24 赫尔森保健股份公司 不对称脲及其医学应用
CN106170485A (zh) * 2014-03-07 2016-11-30 赫尔辛医疗股份公司 对位取代的不对称脲及其医疗用途
CN106170485B (zh) * 2014-03-07 2021-09-03 赫尔森保健股份公司 对位取代的不对称脲及其医疗用途
CN106536518A (zh) * 2014-05-19 2017-03-22 梅里亚股份有限公司 驱蠕虫化合物
CN106536518B (zh) * 2014-05-19 2020-05-12 勃林格殷格翰动物保健美国公司 驱蠕虫化合物
CN113549006A (zh) * 2020-04-26 2021-10-26 江苏恩华药业股份有限公司 一种酰胺衍生物及其应用
CN113549006B (zh) * 2020-04-26 2023-07-21 江苏恩华药业股份有限公司 一种酰胺衍生物及其应用

Also Published As

Publication number Publication date
AU2005267932A1 (en) 2006-02-09
WO2006014136A1 (en) 2006-02-09
IL180548A0 (en) 2007-06-03
MX2007001226A (es) 2007-03-23
CA2576112A1 (en) 2006-02-09
JP2008508353A (ja) 2008-03-21
KR20070043998A (ko) 2007-04-26
BRPI0514035A (pt) 2008-05-27
RU2007105970A (ru) 2008-09-10
SE0401971D0 (sv) 2004-08-02
US20080064706A1 (en) 2008-03-13
EP1781613A1 (en) 2007-05-09
ZA200700683B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
CN1993325A (zh) 作为组胺h3受体配体的哌啶衍生物
CN1993340A (zh) 作为组胺h3受体配体治疗抑郁的新哌啶衍生物
CN1093127C (zh) 哌嗪衍生物
EP1680418A2 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
CN101014581A (zh) 用于治疗抑郁的新哌啶衍生物
CN1146559C (zh) 毒蕈碱性拮抗剂
US7384955B2 (en) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
CN1653063A (zh) (s)-4-氨基-5-氯-2-甲氧基-n-[1-[1-(2-四氢呋喃羰基)-4-哌啶甲基]-4-哌啶基]苯甲酰胺及其制备方法、含有该化合物的药物组合物及其中间体
CN1805956A (zh) 苯并咪唑衍生物、含有它们的组合物、它们的制备以及它们的用途
CN1134695A (zh) 具有血小板凝聚抑制作用的新颖化合物
CN1100057C (zh) 色烯化合物、其制备方法及含有它们的药物组合物
CN1113059C (zh) 用作神经激肽拮抗剂的哌嗪并衍生物
CN1805940A (zh) 苯并咪唑衍生物、含有它们的组合物、它们的制备以及它们的用途
CN1711251A (zh) 4-(苯基-哌嗪基-甲基)苯甲酰胺衍生物及其在治疗疼痛或胃肠疾病中的用途
CN1956962A (zh) 四氢异喹啉磺酰胺衍生物,其制备方法及其在治疗中的应用
WO2008000818A1 (en) Fluorinated indoleamides useful as ligands of the orl-1 receptor
CN100338058C (zh) 新的吲哚衍生物
CN1342152A (zh) N-取代的具有5-羟色胺能活性的酰亚胺衍生物
CN1956959A (zh) 治疗化合物:吡啶n氧化物支架
CN1265658A (zh) 5-萘-1-基-1,3-二噁烷衍生物、它们的制备方法以及它们在治疗中的应用
CN1446211A (zh) 用于治疗cns疾病的吲哚衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070704